The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis

详细信息    查看全文

• 作者：Daniel Karin^a ; ^b ; ^d ; ¹ ; Yukinori Koyama^a ; ^b ; ^c ; ^d ; ¹ ; David Brenner^b ; ^d ; Tatiana Kisseleva^a ; ^d ; ^{tkisseleva@ucsd.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Col ; collagen α1(I) ; α-SMA ; α-smooth muscle actin ; BDL ; bile duct ligation ; CCl4 ; carbon tetrachloride ; qHSCs ; quiescent Hepatic Stellate Cells ; aHSCs ; activated Hepatic Stellate Cells ; aPFs/myofibroblasts ; activated portal fibroblasts /myofibroblasts ; ALT ; alanine aminotransferase ; AST ; aspartate aminotransferase ; TGF-β1 ; Transforming growth factor-β1 ; GFP ; green fluorescent protein
• 刊名：Differentiation
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：92
• 期：3
• 页码：84-92
• 全文大小：828 K

文摘

Liver fibrosis results from chronic injury of hepatocytes and activation of Collagen Type I producing myofibroblasts that produce fibrous scar in liver fibrosis. Myofibroblasts are not present in the normal liver but rapidly appear early in experimental and clinical liver injury. The origin of the myofibroblast in liver fibrosis is still unresolved. The possibilities include activation of liver resident cells including portal fibroblasts, hepatic stellate cells, mesenchymal progenitor cells, and fibrocytes recruited from the bone marrow. It is considered that hepatic stellate cells and portal fibroblasts are the major source of hepatic myofibroblasts. In fact, the origin of myofibroblasts differs significantly for chronic liver diseases of different etiologies, such as cholestatic liver disease or hepatotoxic liver disease. Depending on etiology of hepatic injury, the fibrogenic foci might initiate within the hepatic lobule as seen in chronic hepatitis, or primarily affect the portal areas as in most biliary diseases. It has been suggested that activated portal fibroblasts/myofibroblasts work as “myofibroblasts for cholangiocytes” while hepatic stellate cells work as “myofibroblast for hepatocytes”. This review will focus on our current understanding of the activated portal fibroblasts/myofibroblasts in cholestatic liver fibrosis.